ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

9815	Companies
196869	Keywords
127923	Articles
104690	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’
OSE Immunotherapeutics publie des résultats précliniques prometteurs sur Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans 'Blood', ouvrant de nouvelles perspectives en immunothérapie pour les patients atteints de LAL

Immunothérapie Publication OSE Immunotherapeutics Lusvertikimab Leucémie Aiguë Lymphoblastique
PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
OSE Immunotherapeutics announces publication of preclinical efficacy results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'. Collaboration with University Medical Center Schleswig-Holstein on targeting ALL patients

OSE Immunotherapeutics Lusvertikimab Acute Lymphoblastic Leukemia Blood Journal IL-7 Receptor Antagonist
BRIEF

published on 06/24/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies

OSE Immunotherapeutics Leukemia Memorial Sloan Kettering Cancer Center CAR-T IL-7R
BRIEF

published on 06/24/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics signe un accord stratégique avec MSK pour les thérapies par cellules CAR-T

OSE Immunotherapeutics Leucémie Memorial Sloan Kettering Cancer Center CAR-T IL-7R
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T
OSE Immunotherapeutics annonce un accord avec le Memorial Sloan Kettering Cancer Center pour les thérapies CAR-T. L'accord porte sur des brevets dans le traitement des cancers exprimant l'IL-7R

Brevets OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center IL-7R Thérapies CAR-T
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE

Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
BRIEF

published on 06/20/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress

Autoimmune Diseases OSE Immunotherapeutics FOCIS 2024 IL-35 Therapeutic MRNA
BRIEF

published on 06/20/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics présente des données prometteuses sur la plateforme ARNm au congrès FOCIS

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique FOCIS 2024 IL-35
PRESS RELEASE

published on 06/20/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)
OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique au congrès annuel FOCIS à San Francisco. L'IL-35 joue un rôle clé dans le contrôle des maladies auto-immunes et inflammatoires

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique IL-35 FOCIS
BRIEF

published on 06/05/2024 at 07:35, 1 year 8 months ago

OSE Immunotherapeutics and Nantes University Hospital Present Positive Results in Renal Transplantation

Immunotherapy Clinical Test OSE Immunotherapeutics FR104/VEL-101 Kidney Transplantation

Accesswire

Published on 02/05/2026 at 17:35, 36 minutes ago

Pentagon I Capital Corp. Enters into Letter Agreement to Complete Qualifying Transaction with Prospectiva Resources Ltd.
Published on 02/05/2026 at 16:40, 1 hour 31 minutes ago

Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 15:45, 2 hours 26 minutes ago

American Critical Minerals Recaps a Highly Successful 6 Months and Files Amended and Restated Technical Report
Published on 02/05/2026 at 15:10, 3 hours 1 minute ago

Electric Metals (USA) Limited Announces Change of Auditor
Published on 02/05/2026 at 14:50, 3 hours 21 minutes ago

High Tide Resources Announces Non-Brokered Private Placements

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 17:55, 16 minutes ago

Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 31 minutes ago

BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.
Published on 02/05/2026 at 17:40, 31 minutes ago

UV GERMI : MISE À DISPOSITION DE LA NOTE D’INFORMATION ET DU DOCUMENT « AUTRES INFORMATIONS » DANS LE CADRE DE L’OFFRE PUBLIQUE DE RACHAT D’ACTIONS INITIÉE PAR UV GERMI
Published on 02/05/2026 at 17:05, 1 hour 6 minutes ago

European Research and Innovation: the Politecnico di Milano Launches an Office in Brussels
Published on 02/05/2026 at 16:30, 1 hour 41 minutes ago

Dividend Declaration

Les Echos

Published on 02/05/2026 at 18:06, 4 minutes ago

Aéroports de Paris SA - Actions et droits de vote au 31 janvier 2026
Published on 02/05/2026 at 18:06, 4 minutes ago

Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
Published on 02/05/2026 at 18:00, 11 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of January 30, 2026
Published on 02/05/2026 at 18:00, 11 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 30 janvier 2026
Published on 02/05/2026 at 18:00, 11 minutes ago

ACM - Press release 2025 results

View all LES ECHOS COMFI WIRE